0.357
price down icon6.27%   -0.0239
pre-market  Pre-market:  .36   0.003   +0.84%
loading
Lexicon Pharmaceuticals Inc stock is traded at $0.357, with a volume of 5.22M. It is down -6.27% in the last 24 hours and down -51.84% over the past month. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
See More
Previous Close:
$0.3809
Open:
$0.3745
24h Volume:
5.22M
Relative Volume:
0.84
Market Cap:
$129.05M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-0.4463
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-2.91%
1M Performance:
-51.84%
6M Performance:
-79.00%
1Y Performance:
-85.60%
1-Day Range:
Value
$0.325
$0.38
1-Week Range:
Value
$0.3228
$0.4089
52-Week Range:
Value
$0.2836
$2.62

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Name
Lexicon Pharmaceuticals Inc
Name
Phone
(281) 863-3000
Name
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Employee
285
Name
Twitter
@LexPharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
LXRX's Discussions on Twitter

Compare LXRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
0.357 129.05M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-05-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-17-24 Initiated H.C. Wainwright Buy
Apr-30-24 Initiated Leerink Partners Outperform
Mar-07-23 Initiated Jefferies Hold
Aug-12-22 Initiated Piper Sandler Overweight
Jan-29-21 Upgrade JP Morgan Underweight → Neutral
Jan-29-21 Downgrade Wedbush Outperform → Neutral
Dec-08-20 Upgrade Citigroup Neutral → Buy
Nov-18-20 Upgrade Gabelli & Co Hold → Buy
Dec-11-19 Downgrade Gabelli & Co Buy → Hold
Nov-08-19 Downgrade Citigroup Buy → Neutral
Sep-11-19 Upgrade Gabelli & Co Hold → Buy
Jul-29-19 Downgrade Stifel Buy → Hold
Mar-25-19 Upgrade Gabelli & Co Sell → Hold
Jul-31-18 Reiterated Stifel Buy
Feb-23-18 Downgrade Needham Buy → Hold
Feb-14-18 Downgrade JP Morgan Neutral → Underweight
Mar-01-17 Reiterated H.C. Wainwright Buy
Mar-01-17 Reiterated Wedbush Outperform
Oct-07-16 Initiated H.C. Wainwright Buy
Aug-05-16 Reiterated Wedbush Outperform
Aug-02-16 Initiated Citigroup Buy
Mar-02-16 Reiterated Wedbush Outperform
Nov-09-15 Reiterated Wedbush Outperform
Sep-28-15 Upgrade Gabelli & Co Sell → Hold
Sep-18-15 Downgrade Gabelli & Co Hold → Sell
Aug-10-15 Downgrade JP Morgan Overweight → Neutral
View All

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

pulisher
Mar 12, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Piper Sandler Cuts Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target to $6.00 - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Equities Analysts Issue Forecasts for LXRX Q1 Earnings - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Brokerages - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Lexicon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies - TipRanks

Mar 09, 2025
pulisher
Mar 08, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025
pulisher
Mar 07, 2025

Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

What Analysts Are Saying About Lexicon Pharmaceuticals Stock - Benzinga

Mar 07, 2025
pulisher
Mar 07, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlig - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Lexicon: Q4 Earnings Snapshot - KTEN

Mar 06, 2025
pulisher
Mar 06, 2025

Lexicon Pharma beats Q4 estimates, shares rise on strong revenue - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Lexicon Pharma beats Q4 estimates, shares rise on strong revenue By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian

Mar 06, 2025
pulisher
Mar 06, 2025

Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future? - StockTitan

Mar 06, 2025
pulisher
Mar 05, 2025

Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2 - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Market Perform” Rating at Leerink Partners - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Lexicon Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

When Will Lexicon Pharmaceuticals Reveal Its 2024 Financial Performance? - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Private equity firms who have a significant stake must be disappointed along with institutions after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap dropped by US$148m - Simply Wall St

Mar 04, 2025
pulisher
Mar 03, 2025

Lexicon’s Sunny Take Does Not Sway Investors About Phase IIb DPNP Miss - News & Insights

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On? - Benzinga

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon Pharmaceuticals stock tumbles after clinical study results By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon Pharmaceuticals stock tumbles after clinical study results - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon advances pilavapadin into Phase 3 for diabetic pain - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon advances pilavapadin into Phase 3 for diabetic pain By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider.com

Mar 03, 2025
pulisher
Mar 03, 2025

Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Lexicon Pharma To Announce Topline Results From Phase 2b PROGRESS Study Today - Nasdaq

Mar 03, 2025
pulisher
Mar 02, 2025

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times

Mar 02, 2025
pulisher
Mar 02, 2025

Lexicon Pharmaceuticals to Host Conference Call on Phase 2b Results for Pilavapadin in Diabetic Peripheral Neuropathic Pain - Nasdaq

Mar 02, 2025
pulisher
Mar 02, 2025

Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming - StockTitan

Mar 02, 2025
pulisher
Feb 20, 2025

Lexicon Pharmaceuticals, Inc. Announces Resignation of Praveen Tyle as Executive Vice President, Research and Development, Effective as of April 26, 2021 - Marketscreener.com

Feb 20, 2025
pulisher
Feb 18, 2025

Lexicon to cut 50% of workforce to focus on sotagliflozin - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) - Yahoo Finance

Feb 18, 2025
pulisher
Feb 13, 2025

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain - News & Insights

Feb 13, 2025
pulisher
Feb 10, 2025

Merck: 4 No-Brainer Reasons to Buy This Dip - The Globe and Mail

Feb 10, 2025
pulisher
Feb 06, 2025

Vantage Markets Partners with Scuderia Ferrari HP for a Multi-Year Sponsorship - The Globe and Mail

Feb 06, 2025
pulisher
Feb 05, 2025

Peripheral Neuropathic Pain Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart

Feb 05, 2025
pulisher
Feb 05, 2025

Peripheral Neuropathic Pain Market to Show Remarkable Growth - openPR

Feb 05, 2025

Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):